Back to Search
Start Over
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
- Source :
- Jansen, W J, Ossenkoppele, R, Knol, D L, Tijms, B M, Scheltens, P, Verhey, F R J & Visser, P J 2015, ' Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis ', JAMA, vol. 313, no. 19, pp. 1924-1938 . https://doi.org/10.1001/jama.2015.4668, JAMA-Journal of the American Medical Association, 313(19), 1924-1938. American Medical Association, J. Jansen, W, Ossenkoppele, R, Knol, D L, M. Tijms, B, Scheltens, P, R. J. Verhey, F, Visser, P J & Aarsland, D 2015, ' Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis ', JAMA : the journal of the American Medical Association, vol. 313, no. 19, 313(19), pp. 1924 . https://doi.org/10.1001/jama.2015.4668, JAMA: The Journal of the American Medical Association; 313(19), pp 1924-1938 (2015), JAMA, 313(19), 1924-1938. American Medical Association, Jama, vol. 313, no. 19, pp. 1924-1938, JAMA (Journal of the American Medical Association), Vol. 313, No 19 (2015) pp. 1924-1938, The journal of the American Medical Association 313(19), 1924 (2015). doi:10.1001/jama.2015.4668, Jama : Journal of the American Medical Association, 313, 19, pp. 1924-38, Jama : Journal of the American Medical Association, 313, 1924-38, JAMA
- Publication Year :
- 2015
-
Abstract
- Item does not contain fulltext IMPORTANCE: Cerebral amyloid-beta aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. OBJECTIVE: To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI). DATA SOURCES: Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators. STUDY SELECTION: Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity. DATA EXTRACTION AND SYNTHESIS: Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies. MAIN OUTCOMES AND MEASURES: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations. RESULTS: The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-epsilon4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE epsilon4epsilon4 carriers, 50 years for epsilon2epsilon4 carriers, 55 years for epsilon3epsilon4 carriers, 65 years for epsilon3epsilon3 carriers, and 95 years for epsilon2epsilon3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality. CONCLUSIONS AND RELEVANCE: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
- Subjects :
- Apolipoprotein E
Male
Pediatrics
Alzheimer`s disease Donders Center for Medical Neuroscience [Radboudumc 1]
Neurology
pathology [Cognitive Dysfunction]
Apolipoprotein E4
pathology [Dementia]
Biomarkers/analysis
ddc:616.89
Risk Factors
pathology [Brain]
chemistry [Cerebrospinal Fluid]
80 and over
Prevalence
Medicine
risk factors
Apolipoprotein E4/genetics
genetics [Apolipoprotein E4]
Cerebrospinal Fluid
Cerebrospinal Fluid/chemistry
Aged, 80 and over
Medicine(all)
pathology [Mild Cognitive Impairment]
Adult
Age Factors
Aged
Amyloid beta-Peptides
Biomarkers
Brain
Cognitive Dysfunction
Dementia
Female
Genotype
Humans
Middle Aged
Positron-Emission Tomography
Medicine (all)
Cognitive Dysfunction/pathology
Cognition
General Medicine
analysis [Amyloid beta-Peptides]
Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]
3. Good health
Amyloid beta-Peptides/analysis
Meta-analysis
Alzheimer's disease
analysis [Biomarkers]
medicine.medical_specialty
Amyloid
Dementia/pathology
ta3112
Article
mental disorders
Brain/pathology
ddc:610
Psychiatry
Pathological
Mild Cognitive Impairment/pathology
analysis [Biological Markers]
business.industry
Biological Markers/analysis
medicine.disease
ta3124
business
aged, 80 and over
Subjects
Details
- Language :
- English
- ISSN :
- 00987484 and 15383598
- Database :
- OpenAIRE
- Journal :
- Jansen, W J, Ossenkoppele, R, Knol, D L, Tijms, B M, Scheltens, P, Verhey, F R J & Visser, P J 2015, ' Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis ', JAMA, vol. 313, no. 19, pp. 1924-1938 . https://doi.org/10.1001/jama.2015.4668, JAMA-Journal of the American Medical Association, 313(19), 1924-1938. American Medical Association, J. Jansen, W, Ossenkoppele, R, Knol, D L, M. Tijms, B, Scheltens, P, R. J. Verhey, F, Visser, P J & Aarsland, D 2015, ' Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis ', JAMA : the journal of the American Medical Association, vol. 313, no. 19, 313(19), pp. 1924 . https://doi.org/10.1001/jama.2015.4668, JAMA: The Journal of the American Medical Association; 313(19), pp 1924-1938 (2015), JAMA, 313(19), 1924-1938. American Medical Association, Jama, vol. 313, no. 19, pp. 1924-1938, JAMA (Journal of the American Medical Association), Vol. 313, No 19 (2015) pp. 1924-1938, The journal of the American Medical Association 313(19), 1924 (2015). doi:10.1001/jama.2015.4668, Jama : Journal of the American Medical Association, 313, 19, pp. 1924-38, Jama : Journal of the American Medical Association, 313, 1924-38, JAMA
- Accession number :
- edsair.doi.dedup.....edb06d6180343534a6132840445ac66a